Business Description
JW (Cayman) Therapeutics Co Ltd
ISIN : KYG5210T1040
Share Class Description:
FRA:JNY: Ordinary SharesCompare
Compare
Traded in other countries / regions
02126.Hong KongJWCTF.USAJNY.Germany IPO Date
2023-10-16Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.16 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.87 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.26 | |||||
| Beneish M-Score | -3.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 50.9 | |||||
| 3-Year EPS without NRI Growth Rate | 52.6 | |||||
| 3-Year FCF Growth Rate | 32.6 | |||||
| 3-Year Book Growth Rate | -24.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.99 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 56.41 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.57 | |||||
| 9-Day RSI | 24.92 | |||||
| 14-Day RSI | 26.38 | |||||
| 6-1 Month Momentum % | -17.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.04 | |||||
| Quick Ratio | 3.9 | |||||
| Cash Ratio | 3.8 | |||||
| Days Inventory | 331.15 | |||||
| Days Sales Outstanding | 22.53 | |||||
| Days Payable | 50.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | -28.08 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.08 | |||||
| Operating Margin % | -351.89 | |||||
| Net Margin % | -433.57 | |||||
| FCF Margin % | -279.15 | |||||
| ROE % | -18.32 | |||||
| ROA % | -14.92 | |||||
| ROIC % | -21.18 | |||||
| 3-Year ROIIC % | 45.86 | |||||
| ROC (Joel Greenblatt) % | -100.7 | |||||
| ROCE % | -16.74 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.36 | |||||
| PB Ratio | 0.28 | |||||
| Price-to-Tangible-Book | 0.48 | |||||
| EV-to-EBIT | 0.55 | |||||
| EV-to-EBITDA | 0.56 | |||||
| EV-to-Revenue | -2.35 | |||||
| EV-to-FCF | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 0.78 | |||||
| Price-to-Net-Cash | 0.88 | |||||
| Earnings Yield (Greenblatt) % | 180.97 | |||||
| FCF Yield % | -52.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JW (Cayman) Therapeutics Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 11.308 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 26.38 | ||
| 14-Day ATR (€) | 0.005582 | ||
| 20-Day SMA (€) | 0.1539 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.137 - 0.3295 | ||
| Shares Outstanding (Mil) | 414.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JW (Cayman) Therapeutics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JW (Cayman) Therapeutics Co Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
JW (Cayman) Therapeutics Co Ltd Frequently Asked Questions
What is JW (Cayman) Therapeutics Co Ltd(FRA:JNY)'s stock price today?
The current price of FRA:JNY is €0.14. The 52 week high of FRA:JNY is €0.33 and 52 week low is €0.14.
When is next earnings date of JW (Cayman) Therapeutics Co Ltd(FRA:JNY)?
The next earnings date of JW (Cayman) Therapeutics Co Ltd(FRA:JNY) is .
Does JW (Cayman) Therapeutics Co Ltd(FRA:JNY) pay dividends? If so, how much?
JW (Cayman) Therapeutics Co Ltd(FRA:JNY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers